NDAINJECTIONINJECTABLE
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Fosun Pharma is mechanism of action nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. First approved in 2009.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride is a calcium channel blocker administered by injection for acute hypertension management. It selectively inhibits calcium ion influx into vascular smooth muscle, causing vasodilation without significantly affecting cardiac contractility. The injectable formulation enables rapid blood pressure control in acute care settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting smaller commercial team and focus on operational efficiency rather than growth investment.
Mechanism of Action
Mechanism of Action Nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine hydrochloride positions you in a mature, stable injectable product with focus on operational excellence and market defense rather than commercial expansion. Career development on this asset emphasizes efficiency, regulatory maintenance, and strategic market access in acute care settings.
Brand Manager
Worked on NICARDIPINE HYDROCHLORIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.